Abstract: A separating material superior to conventional separating materials, and a separation method are provided, with which 1,3-butadiene is selectively separated and recovered from a mixed gas including 1,3-butadiene and C4 hydrocarbons other than 1,3-butadiene. A metal complex, which comprises a dicarboxylic acid compound (I) (see (I) below) represented by general formula (I), an ion of a metal such as beryllium, and a dipyridyl compound (II) represented by general formula (II), namely L-Z-L (II) (see L below), is characterized by including, as the dipyridyl compound (II), at least two different dipyridyl compounds (II). The metal complex is used as a 1,3-butadiene separating material. Formula (I) L is represented by any of the compounds below.

Abstract: A separating material superior to conventional separating materials, and a separation method are provided, with which 1,3-butadiene is selectively separated and recovered from a mixed gas including 1,3-butadiene and C4 hydrocarbons other than 1,3-butadiene. A metal complex, which comprises a dicarboxylic acid compound (I) (see (I) below) represented by general formula (I), an ion of a metal such as beryllium, and a bipyridyl compound (II) represented by general formula (II), namely L-Z-L (II) (see (L) below), is characterized by including, as the dicarboxylic acid compound (I), at least two different dicarboxylic acid compounds (I). The metal complex is used as a 1,3-butadiene separating material. Formula (I) L is represented by any of the compounds below. Formula (L).

Abstract: A novel emitter compound having the formula Os(L1)(L2)(L3) and a novel method of making such compounds are disclosed. In the formula Os(L1)(L2)(L3), each of L1, L2, and L3 is independently a bidentate ligand. The method includes (a) reacting a precursor of ligand L1 with an osmium precursor to form a first intermediate product that has the ligand L1 coordinated to the osmium, wherein the osmium precursor has the formula OsHx(PR3)y, wherein x is an integer from 2 to 6 and y is an integer from 2 to 5, and R is selected from the group consisting of aryl, alkyl and cycloalkyl; (b) reacting the first intermediate product with a reducing agent to form a Os(II) second intermediate product; (c) reacting the second intermediate product with a coordinating solvent to form a third intermediate product; and (d) reacting a mixture of ligands L2 and L3 with said third intermediate product.

Abstract: The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Abstract: Inhibitors of BACE1 and compositions containing them are described. Use of the inhibitors and compositions containing them to treat Alzheimer's disease are described.

Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Abstract: The invention relates to compositions including porous biomolecule-containing metal-organic frameworks and methods for their preparation. The porous biomolecule-containing metal-organic frameworks can include a metal component and a biomolecule component. The pores located within the frameworks have a pore space and said pore space is capable to adsorb materials therein. These compositions of the invention are useful in a wide variety of applications, such as, but not limited to, hydrogen and carbon dioxide sequestration, separation and storage; carbon dioxide uptake; and drug storage and release.

Abstract: The invention provides methods and compositions for labeling dithiol-containing analytes, including a substituted, optionally hydro-, optionally hetero-, monoarsenical anthracene compound comprising a 4? rotation blocking group and a 5? arsenic, and that exhibits a detectable increase or shift in fluorescence when the arsenic reacts with two thiols of a rotation-blocking binding target molecule.

Abstract: The present invention provides bimetallic complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to one or more active metal centers of the complex.

Abstract: The invention describes a crystallized hybrid solid with an organic-inorganic matrix, of three-dimensional structure, containing an inorganic network of zinc-based metal centers connected to one another by organic ligands constituted by the entities —O2C—C6H3—N3—CO2— and C6H12N2. Said solid is called DMOF-1-N3 and has an X-ray diffraction diagram as provided below.

Abstract: Provided is a colored photosensitive curing composition useful for color filters in primary colors, including blue, green, and red, having a high molar absorption coefficient and allowing a reduction in film thickness and superior color purity and fastness. A colored photosensitive curing composition, comprising, as its colorant, a dipyrromethene-based metal complex compound obtained from a metal or metal compound and a dipyrromethene-based compound represented by the following Formula (I): wherein in Formula (I), R1 to R6 each independently represent a hydrogen atom or a substituent group; and R7 represents a hydrogen or halogen atom, or an alkyl, aryl or heterocyclic group.

Abstract: The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Abstract: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.

Abstract: A large single crystal of a complex such as an organic carboxylic acid metal complex, which crystal is useful as an adsorbent of various gases and vapors of organic solvents and as a hydrogen-absorbing material, as well as a process for producing the crystal, is disclosed. Two layers wherein an upper layer thereof is constituted by a solution containing a metal salt and an organic carboxylic acid having a conjugated system, or a solution containing a metal salt of the organic carboxylic acid having a conjugated system, and wherein a lower layer of the two layers is constituted by a solvent which is not miscible with the solvent of the solution, is formed. Vapor of pyrazine or a substituted pyrazine from a solution of pyrazine or the substituted pyrazine is introduced into the upper layer to allow reaction, thereby forming a large single crystal(s) of the organic carboxylic acid metal complex at the interface between the two layers, which crystal(s) has(have) a longer side with a size of not less than 0.8 mm.

Abstract: The invention provides methods and compositions for labeling dithiol-containing analytes.

Abstract: The invention provides novel synthetic intermediates and processes that can be used to prepare compounds of formula (I), wherein R1 has any of the values described herein and R2 is a nucleoside sugar group.

Abstract: The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to novel ionic liquid compositions.

Abstract: Heteromolecular metal-humic organic complexes of the type: (A)n-(Metal)x-(B)m where A is one or several humic complexes which may be totally or partially sulfonated or may have been treated with an amine in order to protect the carboxylic groups from interacting with polyvalent cations, and B is a non-humic complexing (organic chelating agent) compound, the biological and chemical stability whereof allows for protection of the metal and the multitoothed or multi-valent molecule involved in the complex against degradation phenomena, both chemical and microbiological, having the beneficial effect of humic acid, as an effective plant growth and nutrition stimulant and as a metabolic and immune system activator in animals and humans.

Abstract: The present invention relates to compositions including porous biomolecule-containing metal-organic frameworks and methods for their preparation. The porous biomolecule-containing metal-organic frameworks can include a metal component and a biomolecule component. The pores located within the frameworks have a pore space and said pore space is capable to adsorb materials therein. These compositions of the present invention are useful in a wide variety of applications, such as, but not limited to, hydrogen and carbon dioxide sequestration, separation and storage; carbon dioxide uptake; and drug storage and release.

Abstract: The present invention relates to processes for preparing a porous metal-organic framework comprising at least two organic compounds coordinated to at least one metal ion, the porous metal-organic frameworks prepared by the process and their use, in particular for gas storage and gas separation.

Abstract: The present invention provides a composition comprising zinc and trimethoprim, particularly in a weight ration of about 1:3 to about 1:7, as well as a sustained- or prolonged-release preparation which comprises trimethoprim and zinc and a biodegradable polymer providing a clinically useful composition which has prolonged release over a long period of time.

Abstract: Precursors for use in depositing metal-containing films on substrates such as wafers or other microelectronic device substrates, as well as associated processes of making and using such precursors, and source packages of such precursors. The precursors are useful for depositing Ge2Sb2Te5 chalcogenide thin films in the manufacture of nonvolatile Phase Change Memory (PCM) devices, by deposition techniques such as chemical vapor deposition (CVD) and atomic layer deposition (ALD).

Abstract: The invention concerns compounds, oligomers, and polymers that contain: (I), (II), (III), or (IV) groups; where “-” indicates points of attachment.

Abstract: A large single crystal of a complex such as an organic carboxylic acid metal complex, which crystal is useful as an adsorbent of various gases and vapors of organic solvents and as a hydrogen-absorbing material, as well as a process for producing the crystal, is disclosed. Two layers wherein an upper layer thereof is constituted by a solution containing a metal salt and an organic carboxylic acid having a conjugated system, or a solution containing a metal salt of the organic carboxylic acid having a conjugated system, and wherein a lower layer of the two layers is constituted by a solvent which is not miscible with the solvent of the solution, is formed. Vapor of pyrazine or a substituted pyrazine from a solution of pyrazine or the substituted pyrazine is introduced into the upper layer to allow reaction, thereby forming a large single crystal(s) of the organic carboxylic acid metal complex at the interface between the two layers, which crystal(s) has (have) a longer side with a size of not less than 0.8 mm.

Abstract: The invention provides an optical information recording medium having at least a substrate and a recording layer capable of recording information provided on the substrate. The recording layer contains at least a metal complex compound obtained by forming a salt from a cationic part and an anionic part, and the cationic part being a cation of a metal complex having a molar absorbance coefficient (?) in the wavelength range of 350 to 1300 nm of 10,000 dm3 mol?1 cm?1 or less when an anionic part is any one of Cl?, Br?, I?, ClO4?, PF6?, BF4?, SO42?, or CF3SO3?. A thermal decomposition temperature of the metal complex is preferably 250° C. or higher when an anionic part of any one of Cl?, Br?, I?, ClO4?, PF6?, BF4?, SO42?, or CF3SO3?.

Abstract: Heteromolecular metal-humic organic complexes of the type: (A)n-(Metal)x-(B)m where A is one or several humic complexes which may be totally or partially sulfonated or may have been treated with an amine in order to protect the carboxylic groups from interacting with polyvalent cations, and B is a non-humic complexing (organic chelating agent) compound, the biological and chemical stability whereof allows for protection of the metal and the multitoothed molecule involved in the complex against degradation phenomena, both chemical and microbiological, having the beneficial effect of humic acid, as an effective plant growth and nutrition stimulant and as a metabolic and immune system activator in animals and humans.

Abstract: The present invention relates to processes for preparing a porous metal-organic framework comprising at least two organic compounds coordinated to at least one metal ion, the porous metal-organic frameworks prepared by the process and their use, in particular for gas storage and gas separation.

Abstract: An improved one-pot process for the preparation of Ceftiofur of the formula (I) or its salt, without isolating intermediate compound

Abstract: The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and which are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: Complexes of a selected class of chiral ligands with molybdenum, tungsten or chromium, preferably molybdenum, are effective as catalysts in highly enantioselective and regioselective alkylation of allylic substrates. Such compositions provide a versatile and low-cost alternative to existing catalysts.

Abstract: The compounds of the invention are represented by the following general structure 1

Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.

Abstract: Novel organic arsonic compounds are described as tumor inhibiting, and cancer treating compounds. Methods and compositions for inhibiting tumor cells and treating cancer are also provided.

Abstract: The present invention relates to chemical compounds having the formula: or a pharmaceutically acceptable salt thereof. R1 is selected from the group consisting of: R2 is selected from the group consisting of hydrogen, CH3—, FCH2—, F2CH— R3 is selected from the group consisting of: X is selected from the group consisting of hydrogen, halogen, cyano, —NH2, —N(CH3)2, —HSO2NH2, —SO2NH2 and —SCH3. The subscript n is 0 or 1.

Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling. The compounds have the following formulas where R1, R2 and R3 are defined in the written description of the invention.

Abstract: Novel organic arsenic compounds are described as cytotoxic agents with potent anti-tumor activity against cancer cells and particularly, with regard to human leukemic cells and breast cancer cells.

Abstract: The invention is based on the discovery that a new class of molecular rectangles can be prepared by using a stepwise synthesis plan under mild temperature conditions. The new rectangles are neutral and exhibit luminescence in solution at room temperature.

Abstract: Novel organic arsenic compounds are described as cytotoxic agents with potent anti-tumor activity against cancer cells and particularly, with regard to human leukemic cells and breast cancer cells.

Abstract: The present invention relates to novel metal chelates, exemplified as technetium-99m or rhenium chelates, and to the process of preparing such metal chelates from corresponding ligands. These ligands and their corresponding metal chelates are synthesized to have a cysteinylethylene (EC) structure, a monothiourea (MTU) structure, or a dithiourea (DTU) structure. The present invention further relates to a pharmaceutical composition comprising a metal chelate, for example, a .sup.99m Tc-chelate, to the use of the composition for renal imaging and examination of renal function, and to a kit for preparing such a composition prior to use.

Abstract: A phenanthridine derivative metal complex of formula 1 having a large absorption in the near-infrared range and a reduced absorption in the visible range, which phenanthridine derivative metal complex is used in a transparent recording medium: ##STR1## where M is a metal atom, and X is a negative ion.

Abstract: An acridine derivative metal complex of formula 2 having a large absorption in the near-infrared range and a reduced absorption in the visible range, which acridine derivative metal complex is used in a transparent recording medium: ##STR1## where M is a metal atom, and X is a negative ion.

Abstract: An electroluminescent device comprised of a metal thioxinoid of the formula ##STR1## wherein M represents a metal; each n is a number of from 1 to 3; N is nitrogen, S is sulfur, and Z represents an aromatic moiety.

Abstract: A photostable cyanine dye possessing a structure represented by the general formula I or II:.PHI..sup.+ -L=.PSI..multidot.Q.sup.- (I).PHI.=L-.PSI..sup.+ .multidot.Q.sup.- (II)wherein .PHI. denotes a monovalent or divalent residue of thiazole ring, oxazole ring, selenazole ring, imidazole ring, pyridine ring, indolenine ring, benzoindolenine ring or dibenzoindolenine ring which may have an aromatic ring condensed thereto, .PSI. denotes a divalent or monovalent residue of thiazole ring, oxazole ring, selenazole ring, imidazole ring, pyridine ring, indolenine ring, benzoindolenine ring or dibenzoindolenine ring which may have an aromatic ring condensed thereto, L denotes a polymethine connecting group for the formation of a cyanine dye, and Q.sup.- denotes an anion represented by the general formula III: ##STR1## wherein M denotes a transition metal atom, R.sup.1, R.sup.2, R.sup.3 and R.sup.

Abstract: The present invention provides compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof.

Abstract: Stable electron acceptor compositions are composed of a plurality of pillared metal complexes disposed on a supporting substrate. At least one Group VIII metal at zero valence is entrapped within this matrix. The complexes comprise from one to about 100 units of the formula:--(Y.sup.1 O.sub.3 --Z--Y.sup.2 O.sub.3)Me.sup.1 --Y.sup.1 and Y.sup.2 being phosphorus or arsenic; Z being a divalent group which reversibly forms a stable reduced form and contains two conjugated cationic centers having a negative E.degree..sub.red value; and Me.sup.1 being a trivalent or tetravalent metal of Group III, IVA, or IVB having an atomic number of at least 21 or a lanthanide. The units are bound to the substrate through a divalent linking group. Counter anions balance the charge of Z. The compositions can be used in the decomposition of water to yield hydrogen gas, the sensing of oxygen, and as catalysts.

Abstract: Pharmaceutical or cosmetic composition intended to be used, by topical application, for retarding hair loss and for inducing or stimulating hair growth, containing at least one compound of formula: ##STR1## where: R.sub.1 denotes H or C.sub.1 -C.sub.8 alkyl;R.sub.2 denotes C.sub.1 -C.sub.8 alkyl or NHR.sub.3, where R.sub.3 denotes H or --COOR.sub.4, where R.sub.4 denotes C.sub.1 -C.sub.4 alkyl;X denotes ##STR2## --OR.sub.9 or --SR.sub.10 ; R.sub.5 and R.sub.6 denote H, optionally substituted C.sub.1 -C.sub.12 alkyl, or C.sub.2 -C.sub.12 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, aralkyl or aryl, or form, with N, a saturated or unsaturated heterocycle;R.sub.9 denotes optionally substituted C.sub.1 -C.sub.12 alkyl, or C.sub.2 -C.sub.12 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.7 -C.sub.12 aralkyl or phenyl, which may optionally be substituted;R.sub.10 is identical to R.sub.9 ; andY denotes O or OSO.sub.3.sup..crclbar. ;as well as its cosmetically or pharmaceutically acceptable acid addition salts.

Abstract: .alpha.-Arylacrylates substituted by a heterocyclic radical and of the general formula I ##STR1## where R.sup.1 is alkoxy or alkylthio, R.sup.2 is alkyl, Het is pyridyl, pyridone, quinolyl, pyrimidinyl, pyrimidinone, the heterocyclic ring system being unsubstituted or substituted, A is carbonyloxy, oxygen or sulfur, and n is 0 or 1, and their plant-tolerated acid addition salts and metal complexes, and the N-oxides of the heterocyclic compounds, and fungicides containing these compounds.

Abstract: Novel xanthine compounds represented by the following formula: ##STR1## wherein each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents; ##STR2## where ----- represents a single bond or a double bond; Y represents a single bond or alkylene, n represents 0 or 1, each of W.sup.1 and W.sup.2 independently represents hydrogen, lower alkyl or amino, Z represents --CH.sub.2 -, --O--, --S-- or --NH--; represents ##STR3## each of R.sup.1 and R.sup.2 independently represents hydrogen, lower alkyl, allyl or propargyl; and R.sup.3 represents hydrogen or lower alkyl, and when Q represents the groups other than ##STR4## each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;provided that when Q is ##STR5## then R.sup.1 R.sup.2 and R.sup.3 are notsimultaneously methyl; and pharmaceutically acceptable salts thereof have a diuretic effect, a renal-protecting effect and a bronchodilatory effect.